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Abstract 
Background: Our study aims to compare acute myocardial injury biomarker rise after atrial 
fibrillation ablation performed with different technologies.
Methods and Results: One hundred and ten patients were treated with pulmonary vein 
isolation with 4 different technologies: open-irrigated tip radiofrequency (RF) catheter in  
35 patients (Group A), cryoballoon in 35 patients (Group B), visually guided laser balloon in 
20 patients (Group C), open-irrigated tip RF catheter with contact-force-sensing technology in  
20 patients (Group D). Post-procedure samples of cardiac troponin I (cTnI) and creatinine kinase- 
-MB (CK-MB) were collected at 19 ± 3 h and 43 ± 3 h after ablation. At the first postprocedur-
al sample, cTnI and CK-MB levels were found elevated in all 110 patients with a median value 
of 2.11 ng/mL and 8.95 ng/mL, respectively. Group B showed cTnI levels increased (median 
5.96 ng/mL) compared to other groups (median Group A: 1.72 ng/mL, Group C: 1.54 ng/mL, 
Group D: 2.0 ng/mL; p < 0.001). Also CK-MB levels resulted higher in cryoablation (median 
26.4 ng/mL) compared to other groups (median Group A: 6.40 ng/mL, Group C: 7.15 ng/mL, 
Group D: 6.50 ng/mL; p < 0.001). No significant association was observed between biomarker 
levels and recurrences of atrial fibrillation after a mean follow-up of 369 ± 196 days.
Conclusions: Highest markers for myocardial injury were observed in the cryoballoon group. 
It is possible that a longer delivery energy duration and other factors affecting lesion size 
resulted in higher amount of cardiac injury in cryoablation. The higher levels of cardiac bio-
markers did not translate into a better outcome and its physiologic significance is unknown. 
(Cardiol J 2014; 21, 5: 516–523)
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atrial fibrillation ablation, myocardial injury
Introduction
Pulmonary vein (PV) isolation has become 
the mainstay of interventional treatment of pa-
roxysmal atrial fibrillation (AF) using catheter 
ablation [1]. Nevertheless, recovery of conduction 
between the PVs and the left atrium is relatively 
common after a successful initial procedure and 
it is strictly related to arrhythmia recurrence [2]. 
Permanent lesion creation has been the target of 
new technological improvements in ablation cat-
heters. Initially the catheter tip irrigation allowed 
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to perform more extensive lesions; more recently 
these catheters have been strengthened with the 
assistance of contact-force-sensing technology to 
ensure a real-time, objective measure of contact 
force between the catheter tip and the beating 
heart wall during ablation. Furthermore, durability 
of lesion can be ameliorated by the utilization of 
new ablation catheter configurations, for example 
balloon catheters, or by the utilization of alternative 
sources of energy, such as cryothermal and laser 
energies [3, 4].
As several markers have been proven to be 
useful for diagnosis and evaluation of size of myo-
cardial injury after acute ischemic episode, many 
authors tried to implement different biomarkers to 
evaluate and quantify the size of effective ablation 
lesions [5–18]. On one hand, previous studies have 
univocally shown humoral biomarkers for myo-
cardial injury to be elevated after radiofrequency 
(RF) ablation, depending on the amount of energy 
delivered and the site of ablation [5]. On the other 
hand, contrasting data exist about myocardial inju-
ry biomarker trend after cryoablation procedures 
[6–9]. Furthermore, to date, no data have been 
available on these biomarkers after laser balloon 
ablation or after RF catheter ablation with the 
assistance of contact-force-sensing technology. In 
addition, it is unknown whether myocardial injury 
biomarker could predict persistent lesion at long-
-term follow-up and which is its role with regards 
to arrhythmia recurrence.
The purpose of this study was to compare 
cardiac troponin I (cTnI) and creatinine kinase 
isoenzyme MB (CK-MB) rise after AF ablation 
performed with 1 of 4 different technologies: 
conventional irrigated tip RF catheter, cryoballo-
on, visually guided laser balloon, irrigated tip RF 
catheter with contact-force-sensing technology. 
In addition, the biomarker rise was associated to 
clinical outcomes during follow-up.
Methods
Study population
We prospectively enrolled 110 consecutive 
patients suffering from drug refractory paroxysmal 
AF and admitted to our institution to perform 
catheter ablation. Paroxysmal AF was defined as 
episodes which converted spontaneously to sinus 
rhythm within 7 days or were sometimes termina-
ted by electrical or pharmacological cardioversion 
within 48 h. Patients were randomized to PV isola-
tion with either conventional open-irrigated tip RF 
catheter (35 patients, Group A) or with cryoballoon 
catheter (35 patients, Group B), or with visually 
guided laser balloon (20 patients, Group C), and 
open-irrigated tip RF catheter with contact-force-
-sensing technology (20 patients, Group D). Only 
patients with normal baseline values for myocardial 
injury were included. We excluded patients with 
renal failure, myopathy, recent myocardial ischemia 
or clinical signs of infection.
Ablation procedure
Informed consent was obtained from all pa-
tients. Transseptal puncture was performed under 
fluoroscopic guidance only or with the adjunct 
of intracardiac echocardiography at physician’s 
discretion. After transseptal puncture, intravenous 
heparin was used to maintain an activated clotting 
time of 300–400 s. In all procedures, an esophageal 
temperature probe was used to monitor esopha-
geal temperature changes during energy delivery. 
Energy delivery duration  was also calculated and 
recorded.
Conventional open-irrigated tip  
RF catheter ablation
A single or double transseptal puncture was 
performed at physician’s discretion. For RF abla-
tion, an open irrigated-tip catheter with a 3.5-mm-
-tip electrode (ThermoCool, Biosense Webster) 
was used in conjunction with a 3-dimensional 
electroanatomic mapping system (CARTO 3, Bio-
sense Webster or NavX Fusion, St. Jude Medical). 
RF energy was delivered with power of up to 35 W 
and a maximum temperature of 43°C. Ablation was 
performed circumferentially, guided by a circular 
mapping catheter, near the antrum of each PV. The 
procedural endpoint was PV isolation as confirmed 
by the circumferential mapping catheter and pacing 
maneuvers (Lasso, Biosense Webster, Diamond 
Bar, CA, USA).
Cryoballoon ablation
A single or double transseptal puncture was 
performed according to the use of a conventional 
circumferential mapping catheter or the custo-
mized mapping catheter Achieve (Medtronic, 
Minneapolis, MN, USA). Positioning of the 28-mm 
or 23-mm diameter cryoballoon (Artic Front Med-
tronic, Minneapolis, MN, USA) was achieved using 
the guidewire and the 12.5 Fr-steerable sheath 
(Flexcath Medtronic Minneapolis, MN, USA). 
Only in 5 patients we adopted a second generation 
mapping catheter (Arctic Front Advance Cardiac 
CryoAblation Catheter System Medtronic, Minnea-
polis, MN, USA).
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Because of a risk of right phrenic nerve palsy, 
while delivering cryoenergy to right PVs, a 6 F 
quadripolar catheter was positioned in the supe-
rior vena cava for phrenic nerve stimulation. After 
confirmation of PV occlusion by contrast injection, 
the 5-min freezing cycle was initiated (4-min with 
Arctic Front Advance). After 2 freezing cycles, PV 
isolation was assessed by circumferential mapping 
catheter.
Visually guided laser balloon ablation
Two transseptal punctures were performed 
for the ablation catheter and multipolar mapping 
catheter. After the dedicated 15 Fr deflectable she-
ath (Cardiofocus Inc.) was placed in the left atrium, 
the balloon catheter was inserted, inflated within 
the atrium, and sequentially positioned at each 
PV ostium. Energy delivery was performed with 
a power of 8.5–10 Watt for 20 s. Before delivery 
of energy to the right PVs, a pacing catheter was 
positioned within the superior vena cava for phre-
nic nerve stimulation. A Lasso catheter was used 
to interrogate each PV before and after ablation 
to assess whether electric isolation was achieved.
Open-irrigated tip RF catheter ablation 
with contact-force-sensing technology
Patients’ instrumentation was performed as 
in conventional procedures. All ablations were 
performed with a contact force sensing catheter 
(TacticathTM Endosense SA, or Contact TherapyTM 
Cool PathTM St. Jude Medical), which is a 7 Fr, open 
irrigated-tip catheter. The ablation catheter was 
connected through the splitter unit simultaneously 
to the RF generator and the force sensing base sy-
stem. Energy delivery duration, mean contact force 
and force time integral (FTI) were also recorded 
and calculated.
Blood sampling and Biomarker  
measurements
Baseline blood tests were drawn at the time 
of hospital admission the day before the scheduled 
procedure in all patients (cTnI and CK-MB). Post-
-procedure samples were collected in the following 
2 mornings after ablation.
Serum samples were processed at our hos-
pital’s central laboratory facility. Within 30 min of 
collection, samples were centrifuged. cTnI was 
measured with the commercially available Access® 
AccuTnITM assay (Beckman Coulter, Chaska, MN), 
CK-MB were tested by separate enzymatic com-
mercially available test kits (CK-MB test). CK-MB 
and cTnI cut-off values (≥ 6.5 ng/mL, ≥ 0.1 ng/mL, 
respectively) were treated as pathologically 
increased.
Postablation management and follow-up
Regular follow-up consisted of outpatient 
clinic visits at 1, 3, 6, and 12 months after the 
procedure and included a detailed history, physical 
examination, 12-lead electrocardiogram, 24-h or 
7-day Holter monitoring. Recurrence of AF post 
ablation is defined as a recurrence of AF more than 
3 months following AF ablation. Episodes of atrial 
tachycardia or atrial flutter should also be classified 
as a “recurrence”. Recurrence rates were analyzed 
with a postprocedural blanking period of 3 months.
Statistical analysis
Data are reported as mean ± standard devia-
tion. The distribution of variables was assessed by 
Kolmogorov-Smirnov test. Categorical variables, 
presented as counts and percentages, were com-
pared in cross-tabulation tables by means of the 
Pearson c2 test. The non-parametric Kruskal-Wallis 
and Wilkoxon tests were used to investigate differ-
ences among groups. Correlations of serum cTnI 
and CK-MB levels with procedural variables were 
performed using linear regression analysis (Pear-
son). These data were analyzed by the SPSS 20.0 
statistical software (SPSS Italia, Inc., Florence, 
Italy). The threshold of statistical significance was 
set at a p value of < 0.05.
Results
Clinical characteristics
The study population consisted of 110 con-
secutive patients referred for ablation of drug 
resistant AF (76% male, mean age 57.2 ± 11.3 
years). Patients baseline characteristics did not 
differ among groups (Table 1).
Procedural data
The procedural endpoint of complete PV 
isolation was achieved in all 110 patients. In 
Group A patients, all PVs were successfully iso-
lated with a mean of 27 ± 16 pulses with RF and 
a mean energy delivery duration of 2030 ± 695 s. 
No major adverse events were seen. In the 
cryoballoon group (Group B), a total of 133 PVs 
were targeted using the 28-mm balloon and 7 PVs 
using the 23-mm balloon. Mean energy delivery 
duration was 3062 ± 716 s with a mean of 11 ± 3 
applications. Of 140 PVs, 128 (91%) were isolated 
using cryoballoon ablation alone, and 12 (8%) PVs 
were isolated using additional 3.5-mm irrigated-
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tip RF ablation catheter in 10 (28%) patients. No 
major complication occurred. In group C patients, 
there were a total of 78 PVs and one left common 
trunk; all PVs and the common trunk were tar-
geted and successfully isolated. The average laser 
energy delivery duration was 2511 ± 1317 s. All 
PVs remained isolated after a minimum of 30 min 
post-ablation. There was only a case of procedural 
pericardial effusions. In group D patients, there 
were a total of 76 PVs and 2 left common trunks. 
All PVs isolation was obtained with a mean of 
32 ± 13 RF applications and mean energy delivery 
duration of 2069 ± 649 s; the average contact 
force applied was 16 ± 8 g (range 2–44 g) while 
mean total FTI was 37036 ± 12527 g and mean 
FTI/RF application was 1371 ± 1427 g. No major 
complication occurred. Mean energy delivery 
duration differed significantly among four groups 
(p = 0.0001). In our series of 110 patients, 2 (1.8%) 
patients complained chest discomfort 24 h post 
ablation (1 patients post RF ablation, 1 patients 
post cryoballoon). None of the patients had elec-
trocardiographic or echocardiographic changes 
suggesting coronary ischemia.
Table 2 lists the procedural details in all pa-
tients and in the four different groups.
Postprocedural cTnI and CK-MB levels
The cTnI levels and CK-MB were normal in all 
patients pre-ablation and increased in all patients 
after the procedure. The first post procedural 
blood tests were performed at about 15 ± 3 h 
after the beginning of RF ablation procedure. At 
the first postprocedural sample, cTnI levels were 
found elevated in all 110 patients with a median 
value of 2.11 ng/mL (0.20–19.85 ng/mL). Patients 
treated with cryoablation showed levels of cTnI 
significantly increased (5.96; range 2.59–19.85 ng/
mL) compared to the other groups (Group A: 1.72; 
range 0.22–5.73 ng/mL; Group C: 1.54; range 0.20– 
–4.13 ng/mL; Group D: 2.0; range 1.0–7.81 ng/mL) 
(p < 0.001) (Table 3, Fig. 1). Among cryoablation 
group, in patients undergoing cryoablation with 
second generation cryo catheter, we found elevated 
levels of cTnI (median 5.01 ng/mL), but we did not 
make any comparison because in this group we en-
rolled few patients. Also CK-MB levels were signif-
icantly elevated in 73 (66%) patients; in particular 
Table 1. Patients’ baseline characteristics in the four groups.
All patients
(n = 110)
Group 1
(n = 35)
Group 2
(n = 35)
Group 3
(n = 20)
Group 4
(n = 20)
P
Mean age 57 ± 11 56 ± 13 58 ± 12 57 ± 8 58 ± 10 0.85
Male 84 (76%) 28 (80%) 23 (66%) 17 (85%) 16 (80%) 0.33
AF history 44 ± 34 47 ± 41 43 ± 33 50 ± 30 36 ± 27 0.57
Lone AF 58 (53%) 22 (63%) 17 (49%) 9 (45%) 10 (50%) 0.53
Hypertension 40 (36%) 12 (34%) 14 (40%) 8 (40%) 6 (30%) 0.86
LA size [mm] 42.1 ± 5.4 41.9 ± 5.5 41.5 ± 5.1 42.4 ± 5.1 43.2 ± 6.4 0.87
EF [%] 61.9 ± 7.3 62.0 ± 7.8 61.8 ± 7.1 61.7 ± 6.9 62.3 ± 7.4 0.99
CK [UI/L] 103 ± 69 111 ± 74 97 ± 82 105 ± 56 99 ± 69 0.97
CK-MB [ng/mL] 1.73 ± 0.92 1.64 ± 0.78 1.71 ± 0.97 1.89 ± 1.04 1.70 ± 0.89 0.93
cTnI [ng/mL] 0.03 ± 0.01 0.03 ± 0.02 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.98 
Data are reported as mean ± standard deviation; AF — atrial fibrillation; LA — left atrium; EF — ejection fraction; CK — creatinine kinase;  
CK-MB — creatinine kinase-MB; cTnI — cardiac troponin I
Table 2. Procedural data in four different groups.
All patients
(n = 110)
Group 1
(n = 35)
Group 2
(n = 35)
Group 3
(n = 20)
Group 4
(n = 20)
P
Electroanatomic mapping 79 (72%) 33 (94%) 10 (29%) 16 (20%) 20 (100%) < 0.0001
Intracardiac echocardiography 32 (29%) 2 (6%) 6 (17%) 14 (70%) 10 (50%) < 0.0001
Double transseptal puncture 37 (34%) 3 (9%) 13 (37%) 20 (100%) 1 (5%) < 0.0001
Mean energy delivery duration [s] 2030 ± 695 3062 ± 716 2511 ± 1317 2069 ± 649 < 0.0001
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elevated CK-MB values were found in 17 out of 35 
(49%) Group A patients, in all 35 (100%) Group B 
patients, in 11 out of 20 (55%) Group C patients and 
in 10 out of 20 (50%) Group D patients (p < 0.001). 
Patients treated with cryoablation showed sig-
nificantly higher levels of CK-MB (26.4 ng/mL) 
compared to the others (Group A: 6.40 ng/mL, 
Group C: 7.15 ng/mL, and Group D: 6.50 ng/mL) 
(p < 0.001) (Table 3, Fig. 2).
Second post procedural blood tests were per-
formed at about 40 ± 3 h after the beginning of RF 
ablation procedure. cTnI levels were elevated in 
all 110 patients with a median value of 0.96 (range 
0.07–10.06) ng/mL. Patients treated with cryoab-
lation showed significantly higher levels of cTnI 
(2.46; range 0.72–10.06 ng/mL) compared to pa-
tients of Group A (0.80; range 0.08–2.94 ng/mL), 
Group C (0.69; range 0.07–1.45 ng/mL), and 
Group D (0.84; range 0.21–2.75 ng/mL) (p < 0.001) 
(Table 3).
Also CK-MB values were still above the level 
to detect myocardial injury in 19 (17%) patients; in 
particular CK-MB values were found elevated in 
16 (46%) Group B patients, and in 3 (9%) Group A 
patients. Patients treated with cryoablation showed 
significantly higher levels of CK-MB (6.4 ng/mL) 
compared to patients of Group A (2.1 ng/mL), Group C 
(2.7 ng/mL), and Group D (2.48 ± 1.07 ng/mL) 
(p < 0.001). Myocardial injury biomarker values 
are summarized in Table 3.
Clinical outcomes after AF ablation
After 1 year of follow-up, 22 (20%) patients 
had clinical recurrences of AF, 7/35 (20%) patients 
Table 3. Postprocedural cardiac troponin I (cTnI) and creatinine kinase-MB (CK-MB) levels in four diffe-
rent groups.
All patients
(n = 110)
Group 1
(n = 35)
Group 2
(n = 35)
Group 3
(n = 20)
Group 4
(n = 20)
P
cTnI 1 2.11 1.72 5.96 1.54 2.0 < 0.0001
(0.20–19.85) (0.22–5.73) (2.59–19.85) (0.20–4.13) (1.0–7.81)
cTnI 2 0.96 0.80 2.46 0.69 0.84 < 0.0001
(0.07–10.06) (0.08–2.94) (0.72–10.06) (0.07–1.45) (0.21–2.75)
CK-MB 1 8.95 6.40 26.4 7.15 6.50 < 0.0001
(2.30–106.3) (2.3–14.4) (9.40–106.3) (3.60–11.30) (2.3–19.30)
CK-MB 2 3.2 2.1 6.4 2.7 2.2 < 0.0001
(0.90–54.0) (0.90–11.5) (1.89–54.0) (1.6–4.2) (1.1–4.9)
 Data are reported as median and range. All values are in ng/mL; cTnI 1 and CK-MB 1 refer to first postprocedural samples; cTnI 2 and CK-MB 2 
refer to second postprocedural samples.
Figure 1. Cardiac troponin I (cTnI) median value at first 
postprocedural sample in four different groups; RF — 
radiofrequency.
Figure 2. Creatinine kinase-MB (CK-MB) median value 
at first postprocedural sample in four different groups; 
RF — radiofrequency.
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in Group A, 9/35 (25%) in Group B, 3/20 (15%) in 
Group C and 3/20 (15%) in Group D. Because of 
the frequency of clinical symptoms, 10/27 (37%) of 
these patients underwent repeat catheter ablation; 
1 (4%) patient underwent electrical cardioversion; 
the remaining 16/27 (59%) patients were suc-
cessfully treated with a strengthened pharmaco-
logical therapy. Redo procedures were performed 
after a postprocedural blanking period of 3 months 
in 2 patients in the Group A, in 4 patients in the 
Group B, in 2 patients in the Group C and in 2 pa-
tients in the Group D (p = 0.85).
Analysis of biochemical markers  
with procedural and outcome data
We also analyzed correlations of the levels of 
biochemical markers with the procedural data. The-
re was a significant correlation between biomarker 
levels (first procedural sample) and longer energy 
delivery duration (for cTnI: r = 0.90, p = 0.001 
and for CK-MB: r = 0.98, p = 0.001, respectively). 
The median value of cTnI and CK-MB (first post 
procedural sample) between AF recurrences group 
(22 patients) and no recurrences group (88 patients) 
was 2.1 ng/mL and 2.3 ng/mL for cTnI and 8.9 ng/mL 
and 9.1 ng/mL, respectively (Figs. 3, 4). Since these 
median values were similar in the two groups, we 
did not perform any further analysis in order to 
assess an association.
Discussion
In our study, we compare 4 different ablation 
catheter technologies and energy sources for AF 
ablation with regard to their effect on myocardial 
necrosis. We performed AF ablation with one of the 
following technologies: irrigated tip RF catheter, 
cryoballoon, laser balloon, irrigated tip RF catheter 
with contact-force-sensing technology. Myocardial 
injury biomarkers were elevated in all patients un-
dergoing PV isolation without any signs of cardiac 
ischemia by serial 12-lead electrocardiograms. 
Higher values of post-procedural cTnI and CK-MB 
were found in patients undergone cryoablation in 
comparison to patients treated with RF ablation or 
laser balloon. We also found a correlation between 
the levels of biomarkers and energy delivery dura-
tion, with higher values of energy delivery duration 
in cryoballoon group.
Previous studies
As several markers have been proven to be of 
clinical utility for diagnosis and estimation of infarct 
size, many authors tried to implement different 
biomarkers to evaluate and quantify the extent of 
effective ablation lesions. First studies focused on 
RF lesion and it has been demonstrated that cTnI 
and cTnT are more sensitive and specific than CK-
-MB for the diagnosis of myocardial injury after RF 
ablation [5, 6]. It has also been showed that the rise 
of biomarkers and the extent of myocardial damage 
after RF catheter ablation depend on the number of 
RF pulses and site of ablation [12–16, 19]. A lower 
cTn level is expected after RF of focal area with few 
RF lesions. RF ablation of more myocardial tissue 
in the atria, such as in PV isolation, is expected 
to have much higher cTn levels [10–12, 20–25]. 
Figure 4. Creatinine kinase-MB (CK-MB) median value 
at first postprocedural sample in two different groups: 
atrial fibrillation (AF) recurrences (27 patients) and no 
recurrences (83 patients).
Figure 3. Cardiac troponin I (cTnI) median value at first 
postprocedural sample in two different groups: atrial 
fibrillation (AF) recurrences (27 patients) and no recur-
rences (83 patients).
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Previous clinical studies reported contrasting data, 
in the setting of AF ablation, on cardiac biomarkers 
levels after cryoballoon ablation compared to RF 
ablation [7, 13–19, 26]. Kuhne et al. [7] reported 
higher post procedural cTnT levels in RF group 
vs. cryoballoon group. Siklody et al. [10] analyzed 
hs-TnT and showed no significant difference in RF 
ablation and cryoballoon ablation. Only 1 study [6] 
reported increase of TnT levels in patients trea-
ted with cryoablation compared to those treated 
by RF ablation. Our finding that the cryoballoon 
resulted in a more pronounced myocardial injury 
is supported by 2 recent studies reporting higher 
cTnI levels after ablation with cryoballoon when 
comparing the PV ablation catheter using RF [19, 
26]. In our study, the higher cTnI and CK-MB 
levels in cryoballoon group may be explained by 
longer energy delivery duration compared to the 
other groups. Previous AF ablation studies have 
found a correlation between levels of cTnT and RF 
delivery duration and cumulative RF energy [24, 
27, 28], but no data exist regarding other energy 
sources. Apart from the energy delivery duration, 
other factors may contribute to higher degree of 
myocardial injury in cryoablation, as suggested by 
increased levels of biomarkers post ablation. In fact, 
larger lesion can be obtained in both cryo and open 
irrigation RF ablation, depending on the conditions 
under which the lesions are created. Electrode 
orientation, contact pressure and blood velocity 
are the main factors involved in lesion formation. 
During cryoablation larger contact surface between 
the cryoballoon catheter and the endocardial tissue 
and the complete occlusion of the PV minimizing 
convective warming of the local blood velocity may 
create larger lesions [10, 28].
Limitations of the study
Only 2 measurements of biomarkers of myo-
cardial damage levels were performed at 15 ± 3 h 
and 43 ± 3 h and no serial measurements were 
performed to assess a peak in TnI and CK-MB le-
vels. Moreover, it was not possible to evaluate the 
kinetics of cTnI and CK-MB because of the lack of 
serial measurement. There are no published data 
about the release and kinetics of cTnI and CK-MB 
after catheter ablation with different energy sour-
ces so we cannot estabilish any comparison.
Conclusions
Compared to previous studies, we showed 
that cTnI and CK-MB are increased after PV iso-
lation performed with 4 different ablation catheter 
technologies. Cardiac enzyme elevations are not 
specific for ischemia in the setting of chest pain 
after AF ablation. Higher values were found after 
cryoballoon ablation. It is possible that a longer 
delivery energy duration and other factors affecting 
lesion size resulted in higher amount of cardiac 
injury in cryoablation. However, the higher rise 
of cardiac biomarkers with cryoablation did not 
translate into a better clinical outcome and its 
physiologic significance is unknown.
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